Cadrenal Therapeutics Inc (CVKD) Quote

$CVKD $15.42 up 2.80% continued momentum this week.

$CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin… https://finance.yahoo.com/news/cvkd-preparations-continue-phase-3-144100739.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr

$CVKD News: Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
Business Wire
Thu, May 15, 2025 at 7:30 AM EDT 3 min read

In This Article: CVKD

PONTE VEDRA, Fla., May 15, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug candidate, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant that is designed to address unmet needs in anticoagulation therapy.

Cadrenal completed the technical transfer and manufacturing of its tecarfarin drug substance in accordance with current good manufacturing practices (cGMP) earlier this year at a U.S. site of a leading global Contract Development and Manufacturing Organization (CDMO). Manufacturing of the tecarfarin drug product candidate is currently underway.

"We are pleased with the important progress we have made with the supply chain and cGMP manufacturing process for tecafarin," said Quang X. Pham, Chairman & CEO. "This is a key milestone as we support our clinical development strategy and tecarfarin’s potential to provide clinical benefits for patients with cardiovascular disease who require chronic VKA anticoagulation."

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for several indications, extensive clinical and real-world data have shown it can have significant, serious side effects.

Cadrenal is pursuing a pipeline-in-a-product approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib).

Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit https://www.cadrenal.com/ and connect with us on LinkedIn.

Safe Harbor

Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potentially," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding tecarfarin’s potential to provide clinical benefits for patients with cardiovascular disease who require chronic VKA anticoagulation and pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability of tecarfarin to provide clinical benefits for patients with cardiovascular disease who require chronic VKA anticoagulation, the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and other assets and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250515408603/en/

Contacts

Corporate and Investor Relations
Paul Sagan
LaVoieHealthScience
(617) 865-0041
psagan@lavoiehealthscience.com

Media
Andrew Korda
LaVoieHealthScience
(617) 865-0043
akorda@lavoiehealthscience.com

Good morning $CVKD. Great news out!

$CVKD $13.8796 +3.73% in the news as Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update https://finance.yahoo.com/news/cadrenal-therapeutics-reports-first-quarter-120000712.html

Good morning $CVKD

Cadrenal also conducted strategic market opportunity research for multiple indications, including patients with left ventricular assist devices. This research indicates that tecarfarin is uniquely positioned to provide clinical value to patients in the rapidly growing LVAD market, which is projected to nearly double by 2032. This research also showed that tecarfarin has the potential to provide clinical benefit in additional high-need cardiovascular, renal, and mechanical heart valve indications, reinforcing tecarfarin’s potential value proposition for patients.

During the quarter, Cadrenal successfully completed the technical transfer and manufacturing of its tecarfarin drug substance (API) from a CDMO site located in Asia to a CDMO site in the United States. This initiative was done to support the company’s clinical and regulatory development strategy for tecarfarin and to improve supply chain security.

In February 2025, Cadrenal appointed James J. Ferguson, M.D., FACC, FAHA, as Chief Medical Officer to lead the review of business development opportunities to expand the Company’s pipeline and drive the late-stage clinical development of tecarfarin for conditions requiring chronic anticoagulation therapy.

"In the first quarter of 2025, Cadrenal continued to build on the momentum we achieved during 2024," said Quang X. Pham, Chairman & CEO. "The appointment of James Ferguson, M.D., FACC, FAHA, as our Chief Medical Officer positions us for success in reviewing potential assets to add to our portfolio and designing and executing our clinical program for tecarfarin. The finalized Collaboration Agreement with Abbott validates the critical need in the market for a new anticoagulant for patients with left ventricular assist devices (LVADs). And our meeting with the FDA provided additional guidance in the design of a pivotal trial."

$CVKD: Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
News Link:
https://www.businesswire.com/news/home/20250507038192/en/Cadrenal-Therapeutics-Reports-First-Quarter-2025-Financial-Results-and-Provides-Corporate-Update

Watchers will become chasers

This will be a blockbuster 

Strong Buy 💃💃💃🫀

NASDAQ: $CVKD BIG OPPORTUNITY

2025 Projected Revenue: $6.3 million, driven by potential initial commercialization of tecarfarin.

2026 Projected Revenue: $16.8 million, reflecting expected market adoption and growth?

NASDAQ: $CVKD

2025 Projected Revenue: $6.3 million, driven by potential initial commercialization of tecarfarin.

2026 Projected Revenue: $16.8 million, reflecting expected market adoption and growth?

NASDAQ: $CVKD BIG WAVE SOON, STRONG💪💪

2025 Projected Revenue: $6.3 million, driven by potential initial commercialization of tecarfarin.

2026 Projected Revenue: $16.8 million,reflecting expected market adoption and growth?

NASDAQ: $CVKD

Hc Wainwright raises Cadrenal Therapeutics price target to $32 from $3
Buy

Innovative Drug & Partnership: Tecarfarin, developed with Abbott, targets a $2B U.S. market for blood thinners.

NASDAQ: $CVKD

Cadrenal Therapeutics Wins "Anticoagulation Therapy Company of the Year"

$CVKD
-Hc Wainwright raises Cadrenal Therapeutics price target $32
Buy

NASDAQ: $CVKD

Cadrenal Therapeutics Named "Anticoagulation Therapy Company of the Year"

$CVKD-Hc Wainwright raises Cadrenal Therapeutics price target to $32 from $3
Buy

Breaking NEWS:🚨

Cadrenal Therapeutics Wins "Anticoagulation Therapy Company of the Year"

Innovation: Tecarfarin minimizes drug interactions, improves stability, and suits patients with kidney impairment.

NASDAQ: $CVKD Upcoming Catalysts: With trial results and potential FDA approval on the horizon, CVKD is positioned for substantial growth, presenting a strategic opportunity for investors in the biotech space.

NASDAQ: $CVKD Targeting a $2 billion US market and addresses a critical unmet medical need in cardiovascular care during a global health crisis

NASDAQ: $CVKD Cadrenal is collaborating with Abbott on Tecarfarin, a novel blood thinner targeting a $2 billion U.S. market.

Hc Wainwright raises Cadrenal Therapeutics price target to $32 from $3

A nice steady climb

Don’t wait

All the makings of a very big drug with longevity to match. All IMO

The below was reported at the September 16, 2024 update.

“The final protocol will be announced following discussions with the FDA in fall 2024”
It’s fall 2024. Y’all ready?

$CVKD~ $20.00 Target eom

This thing finally moving huh $CVKD

$CVKD BIG NEWS : New Blood Thinner Ready for Phase 3; Initiating Coverage of Cadrenal
Therapeutics, Inc
Zack Smallcap Research report - https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_09162024_CVKD_Bautz.pdf

With all do respect...this one turned out nice...ty.

Anyone know when exactly this meeting with the FDA will take place?

Excellent move, much more to come $CVKD

Heart disease $200 Billion problem and they should have a very nice niche of it with their upcoming treatment. Let’s see gimme $100

Its prime time for news and this is dropping. I say Buy.

I dont understand why this is dropping. I am going to hold though because the price is predicted to get to 52.00.

Volume increasing

$CVKD Chart looks ready to move higher imo https://schrts.co/hfdruFjZ

$CVKD Research Report must Read - https://bigstocks.com/cadrenal-therapeutics/

$CVKD 1 Month bullish chart https://schrts.co/ijBMJKCK

$CVKD Strong buy from #tradingview https://www.tradingview.com/symbols/NASDAQ-CVKD/technicals/

$CVKD Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients https://finance.yahoo.com/news/cadrenal-therapeutics-announces-upcoming-type-130000800.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via
@YahooFinance

$CVKD Volume precedes price action, following trend pattern could see reversal any time any days imo!
https://schrts.co/hGXgHbiy

Fine as wine.....

CVKD 8 BUCKS, LETS SEE 9.00

CVKD HERE COMES 8 BUCKS

CVKD...WE SEE 8 BUCKS TODAY OR TOMORROW

CVKD...8 BUCKS AROUND THE CORNER